[1] 赵继宗,周定标. 神经外科学[M]. 北京:人民卫生出版社,2014:189.
[2] Patel AP, Fisher JL, Nichols E, et al.Global, regional, and national burden of brain and other CNS cancer, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2019, 18(4): 376-393.
[3] Siegel RL, Miller KD, Fuchs HE, et al.Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(6): 7-33.
[4] Strom QT, Patil N, Cioffi G, et al.CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017[J]. Neuro Oncol, 2020, 22(Suppl 2): 1-6.
[5] Zhou M, Wang H, Zeng X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the global burden of disease study 2017[J]. Lancet, 2019, 394(10204): 1145-1158.
[6] GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019BD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Neurol, 2023, 22(8): 685-711.
[7] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019BD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1204-1222.
[8] GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019BD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1223-1249.
[9] 李伟伟,董建梅,秦绪成,等. 1990—2019年江苏省甲状腺癌疾病负担及时间趋势分析[J]. 华南预防医学,2023,49(7):808-812.
[10] 李辉章,杜灵彬. Joinpoint回归模型在肿瘤流行病学时间趋势分析中的应用[J]. 中华预防医学杂志,2020,54(8):908-912.
[11] 严永锋,徐源佑,王军,等. 1972—2016年江苏省启东市脑肿瘤患者生存率趋势分析[J]. 华南预防医学,2023,49(8):960-964.
[12] Bell A.Age period cohort analysis: A review of what we should and shouldn't do[J]. Ann Hum Biol, 2020, 47(2): 208-217.
[13] Feng RM, Zong YN, Cao SM, et al.Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics[J]. Cancer Commun, 2019, 39(1): 22.
[14] 陈磊,徐杰茹,王冕,等. 1990―2019年中国肾癌死亡趋势及其年龄-时期-队列分析[J]. 中华疾病控制杂志,2021,25(9):1026-1033,1111.
[15] 陈慧靖,周尚成. 1990—2019年中国中枢神经系统肿瘤疾病负担变化趋势[J]. 现代预防医学,2023,50(1):1-5.
[16] 项鑫,王乙. 中国人口老龄化现状、特点、原因及对策[J]. 中国老年学杂志,2021,41(18):4149-4152.
[17] Llor C, Moragas A, Bayona C, et al.Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: Randomised placebo controlled trial[J]. BMJ, 2013, 347: 5762.
[18] Hou X, Song Z, Zhang F, et al.Burden of brain and other central nervous system cancer in China, 1990-2019: A systematic analysis of observational data from the global burden of disease study 2019[J]. BMJ Open, 2022, 12(7): e059699.
[19] Chen Y, Kang L, Liu X, et al.Update on aging statistics and geriatrics development in China[J]. J Am Geriatr Soc, 2019, 67(1): 187-188.
[20] 许忠宇. 2001—2015年深圳市肺癌发病的年龄—时期—队列模型分析[D]. 武汉:华中科技大学,2018.
[21] Bittoni MA, Wexler R, Spees CK, et al.Lack of private health insurance is associated with higher mortality from cancer and other chronic diseases, poor diet quality, and inflammatory biomarkers in the United States[J]. Prev Med, 2015, 81: 420-426.
[22] Rosenberg AR, Kroon L, Chen L, et al.Insurance status and risk of cancer mortality among adolescents and young adults[J]. Cancer, 2015, 121(8): 1279-1286.
[23] Niu X, Roche LM, Pawlish KS, et al.Cancer survival disparities by health insurance status[J]. Cancer Med, 2013, 2(3): 403-411.
[24] 曹方政. 医疗保险制度的中日比较研究[D]. 长春:吉林大学,2024.
[25] 马恋,陆智明,宋乃庆. 中国居民果蔬消费与营养发展的趋势预测及战略思考[J]. 西南师范大学学报(自然科学版),2017,42(4):68-75.
[26] Liu X, Yu C, Bi Y, et al.Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China[J]. Public Health, 2019, 172: 70-80.
[27] 李建华. 青岛市城阳区居民死因及疾病负担性别差异研究[D]. 济南:山东大学,2014.
[28] Johnson DR, Leeper HE, Uhm JH.Glioblas-toma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis[J]. Cancer, 2013, 119(19): 3489-3495.
[29] Wang Y, Zhao L, Gao L, et al.Health policy and public health implications of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9(7): 446-461. |
